Susan Chang

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial
    Susan M Chang
    Department of Neurological Surgery, Neuro Oncology Service, University of California at San Francisco, San Francisco, California 94143, USA
    Cancer 100:1712-6. 2004
  2. ncbi Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project
    Susan M Chang
    Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, California 94143 0372, USA
    J Neurosurg 98:1175-81. 2003
  3. ncbi Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs
    Susan M Chang
    Neuro Oncology Service, University of California, San Francisco, CA 94143, USA
    Invest New Drugs 22:427-35. 2004
  4. ncbi Temozolomide in the treatment of recurrent malignant glioma
    Susan M Chang
    Department of Neurological Surgery, University of California San Francisco, San Francisco, California 94143, USA
    Cancer 100:605-11. 2004
  5. ncbi A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report
    Susan M Chang
    University of California Medical Center, San Francisco, CA 94143, USA
    Invest New Drugs 21:429-33. 2003
  6. ncbi Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors
    Susan M Chang
    Department of Neurological Surgery, University of California San Francisco, School of Medicine, 400 Parnassus Avenue A808, San Francisco, CA 94143, USA
    Int J Radiat Oncol Biol Phys 59:1122-6. 2004
  7. ncbi Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
    Susan M Chang
    University of California, San Francisco, San Francisco, CA 94143, USA
    Invest New Drugs 23:357-61. 2005
  8. ncbi GNOSIS: guidelines for neuro-oncology: standards for investigational studies--reporting of surgically based therapeutic clinical trials
    Susan Chang
    Neuro Oncology Service, Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, A 808, San Francisco, CA 94143 0350, USA
    J Neurooncol 82:211-20. 2007
  9. ncbi Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme
    Susan M Chang
    Department of Neurological Surgery, University of California, San Francisco, California 94143 0350, USA
    Neurosurg Focus 20:E4. 2006
  10. ncbi Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium
    Susan M Chang
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0350, USA
    Neuro Oncol 10:631-42. 2008

Research Grants

  1. NABTC Member Intitution Grant (UCSF Project Leader)
    Susan Chang; Fiscal Year: 2007

Collaborators

Detail Information

Publications107 found, 100 shown here

  1. ncbi Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial
    Susan M Chang
    Department of Neurological Surgery, Neuro Oncology Service, University of California at San Francisco, San Francisco, California 94143, USA
    Cancer 100:1712-6. 2004
    ..The objective of the current study was to determine the efficacy and toxicity profile of a combination of these agents before radiotherapy in newly diagnosed AG...
  2. ncbi Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project
    Susan M Chang
    Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, California 94143 0372, USA
    J Neurosurg 98:1175-81. 2003
    ..Factors predicting neurological outcome would also be helpful for patient selection for surgically based clinical trials...
  3. ncbi Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs
    Susan M Chang
    Neuro Oncology Service, University of California, San Francisco, CA 94143, USA
    Invest New Drugs 22:427-35. 2004
    ..The objectives of this study were to determine the pharmacokinetic profile and the maximum tolerated dose of CCI-779 in patients with recurrent malignant gliioma taking EIAEDs...
  4. ncbi Temozolomide in the treatment of recurrent malignant glioma
    Susan M Chang
    Department of Neurological Surgery, University of California San Francisco, San Francisco, California 94143, USA
    Cancer 100:605-11. 2004
    ..The authors describe the efficacy and safety results of their institution's open-label, compassionate-use protocol of temozolomide for patients with recurrent malignant glioma...
  5. ncbi A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report
    Susan M Chang
    University of California Medical Center, San Francisco, CA 94143, USA
    Invest New Drugs 21:429-33. 2003
    ..To compare two different infusion schedules of phenylacetate (PA) in patients with primary brain tumors and to assess the feasibility of the administration in a multi-institutional setting...
  6. ncbi Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors
    Susan M Chang
    Department of Neurological Surgery, University of California San Francisco, School of Medicine, 400 Parnassus Avenue A808, San Francisco, CA 94143, USA
    Int J Radiat Oncol Biol Phys 59:1122-6. 2004
    ..To determine the safety and toxicity of carmustine (BCNU) and temozolomide (TMZ) with radiotherapy (RT) in newly diagnosed anaplastic astrocytoma...
  7. ncbi Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
    Susan M Chang
    University of California, San Francisco, San Francisco, CA 94143, USA
    Invest New Drugs 23:357-61. 2005
    ..CCI-779 is an inhibitor of mTOR. The primary objectives of this study were to determine the efficacy of CCI-779 in patients with recurrent GBM and to further assess the toxicity of the drug...
  8. ncbi GNOSIS: guidelines for neuro-oncology: standards for investigational studies--reporting of surgically based therapeutic clinical trials
    Susan Chang
    Neuro Oncology Service, Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, A 808, San Francisco, CA 94143 0350, USA
    J Neurooncol 82:211-20. 2007
    ....
  9. ncbi Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme
    Susan M Chang
    Department of Neurological Surgery, University of California, San Francisco, California 94143 0350, USA
    Neurosurg Focus 20:E4. 2006
    ..In this paper the authors outline standard therapies and review the emerging role of targeted drug therapy in the treatment of recurrent GBM...
  10. ncbi Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium
    Susan M Chang
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0350, USA
    Neuro Oncol 10:631-42. 2008
    ..It would also include a combined phase 0/I pharmacokinetic study to determine the safety and biologically optimal dose of the agent and to verify successful modulation of the target prior to initiating a larger, phase II efficacy study...
  11. ncbi Multidisciplinary management of adult anaplastic astrocytomas
    S Chang
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
    Semin Radiat Oncol 11:163-9. 2001
    ..Basic science insights, advances in neuroimaging and neuropathology, and novel therapies targeting invasion, angiogenesis, and growth modulation will hopefully lead to improved outcome in this subset of patients with malignant glioma...
  12. ncbi Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma
    Susan M Chang
    Department of Neurological Surgery, UCSF, 505 Parnassus Ave, San Francisco, CA 94143, USA
    J Neurooncol 92:401-15. 2009
    ....
  13. ncbi Clinical trial participation among patients enrolled in the Glioma Outcomes Project
    Susan M Chang
    Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0372, USA
    Cancer 94:2681-7. 2002
    ..The authors evaluated factors that influenced patient enrollment in clinical trials using a prospective, large, multi-institutional registry of patients with malignant glioma...
  14. ncbi Patterns of care for adults with newly diagnosed malignant glioma
    Susan M Chang
    Department of Neurological Surgery, University of California, San Francisco, CA 94143 0350, USA
    JAMA 293:557-64. 2005
    ..Patients with malignant glioma (grade III or IV) face a poor prognosis, and few evidence-based treatment guidelines are available. There is a dearth of prospective data on patterns of care for these patients...
  15. ncbi Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma
    Sandeep Kunwar
    Division of Neuro Oncology, Department of Neurological Surgery, University of California, 400 Parnassus Avenue, A 808, San Francisco, CA 94143 0350, USA
    Neuro Oncol 12:871-81. 2010
    ..There was no survival difference between CB administered via CED and GW. Drug distribution was not assessed and may be crucial for evaluating future CED-based therapeutics...
  16. ncbi GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials
    Susan M Chang
    Department of Neurological Surgery, University of California, San Francisco, CA 94143, USA
    Neuro Oncol 7:425-34. 2005
    ..Our guidelines are summarized in a checklist format that can be used as a framework from which to construct a phase 1 or 2 clinical trial...
  17. ncbi Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study
    Michael D Prados
    Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Ave, Room 808, San Francisco, CA 94143 0372, USA
    Cancer Chemother Pharmacol 61:1059-67. 2008
    ..The goal of the study was to define the maximum tolerated dose (MTD) and to characterize the pharmacokinetics of gefitinib when combined with temozolomide...
  18. ncbi Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study
    Timothy F Cloughesy
    Henry E Singleton Brain Cancer Research Program, University of California, Los Angeles, CA, USA
    J Clin Oncol 23:6647-56. 2005
    ..This study compares the pharmacokinetics and pharmacodynamics of tipifarnib at MTD in patients on and off EIAEDs...
  19. ncbi Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy
    Suja Saraswathy
    Department of Radiology and Biomedical Imaging, UCSF, Box 2532, Byers Hall, 1700 4th Street, San Francisco, CA, 94143 2532, USA
    J Neurooncol 91:69-81. 2009
    ..This information may be important for stratifying patients to specific treatment protocols and for planning focal therapy...
  20. ncbi A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
    Michael D Prados
    University of California, San Francisco, San Francisco, California 94143 0372, USA
    Neuro Oncol 8:189-93. 2006
    ..52) for AG patients. Toxicity for the group included diarrhea and myelosuppression. We conclude that the recommended phase 2 dose of CPT-11 for patients with or without EIAED was ineffective on this schedule, in this patient population...
  21. ncbi Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma
    Michael D Prados
    Department of Neurosurgery, University of California, San Francisco, CA 94143 0372, USA
    Neuro Oncol 8:67-78. 2006
    ..There was a modest pharmacokinetic interaction between erlotinib and temozolomide. The favorable tolerability profile and evidence of antitumor activity indicate that further investigation of erlotinib is warranted...
  22. ncbi 3D 1H MRSI of brain tumors at 3.0 Tesla using an eight-channel phased-array head coil
    Joseph A Osorio
    UCSF UCB Joint Graduate Group in Bioengineering, University of California San Francisco, San Francisco, California 94158 2532, USA
    J Magn Reson Imaging 26:23-30. 2007
    ..To implement proton magnetic resonance spectroscopic imaging (1H MRSI) at 3 Tesla (3T) using an eight-channel phased-array head coil in a population of brain-tumor patients...
  23. ncbi Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas
    Tracy R McKnight
    Department of Radiology, University of California, San Francisco 94107, USA
    J Neurosurg 106:660-6. 2007
    ....
  24. ncbi Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume
    Joonmi Oh
    Magnetic Resonance Science Center, Department of Radiology, University of California, San Francisco, California 94107, USA
    J Magn Reson Imaging 19:546-54. 2004
    ....
  25. ncbi Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme
    Yan Li
    Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94158 2532, USA
    Neuro Oncol 13:546-57. 2011
    ..Our studies suggest that quantitative MRI variables derived from anatomic and physiological MRI provide useful information for predicting outcome in patients with GBM...
  26. ncbi Identifying the needs of brain tumor patients and their caregivers
    Rupa Parvataneni
    Division of Neuro Oncology in the Department of Neurosurgery, University of California, San Francisco, CA 94143, USA
    J Neurooncol 104:737-44. 2011
    ....
  27. ncbi 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI
    Andrea Pirzkall
    Department of Radiation Oncology, University of California, San Francisco, School of Medicine, San Francisco, CA 94143 0226, USA
    Int J Radiat Oncol Biol Phys 59:126-37. 2004
    ....
  28. ncbi Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project
    Edward R Laws
    Department of Neurological Surgery, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    J Neurosurg 99:467-73. 2003
    ..Attempts were made to reduce the impact of selection bias by repeating the data analysis after omitting patients with major negative prognostic factors...
  29. ncbi Pediatric brain tumors: current treatment strategies and future therapeutic approaches
    Sabine Mueller
    Department of Neurology, Division of Child Neurology, University of San Francisco, San Francisco, California, USA
    Neurotherapeutics 6:570-86. 2009
    ..This article will outline current and future therapeutic strategies for the most common pediatric CNS tumors, including primitive neuroectodermal tumors such as medulloblastoma, as well as astrocytomas and ependymomas...
  30. ncbi Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme
    Allen M Chen
    Department of Radiation Oncology, University of California, San Francisco School of Medicine, San Francisco, CA 94143 0226, USA
    Int J Radiat Oncol Biol Phys 69:825-30. 2007
    ..To evaluate the feasibility of gross total resection and permanent I-125 brachytherapy followed by hyperfractionated radiotherapy for patients with newly diagnosed glioblastoma...
  31. ncbi IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era
    Joseph L Wiemels
    Department of Neurosurgery and Epidemiology, UCSF, San Francisco, CA 94143 0441, USA
    Int J Cancer 125:680-7. 2009
    ..These results have implications for the study of immunologic factors in glioma as well as for immunotherapy protocols for treating glioma...
  32. ncbi Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions?
    Tarik Tihan
    Department of Pathology, University of California at San Francisco, San Francisco, CA 94143 0511, USA
    Hum Pathol 37:272-82. 2006
    ..A comprehensive prospective study with advanced radiologic, pathologic, and molecular analyses may be more useful to determine prognostically valuable parameters...
  33. ncbi Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study
    Daniel A Lim
    Department of Neurological Surgery, University of California, San Francisco, 94143, USA
    J Neurooncol 93:349-54. 2009
    ..A large-scale, double-blinded, randomized control trial of LEV versus PHT is required to determine seizure control equivalence and better assess differences in SEs...
  34. ncbi High failure rate in spinal ependymomas with long-term follow-up
    Daniel R Gomez
    Department of Radiation Oncology, University of California, San Francisco, CA 94143, USA
    Neuro Oncol 7:254-9. 2005
    ..The overall high rate of recurrence leads us to recommend radiation to doses of 45 to 54 Gy for all patients who do not have gross total resections, and long, close follow-up...
  35. ncbi Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma
    David A Larson
    Department of Radiation Oncology, University of California, San Francisco, School of Medicine, San Francisco, CA 94143 0226, USA
    Int J Radiat Oncol Biol Phys 54:1397-404. 2002
    ..To assess the outcome of high central dose Gamma Knife radiosurgery plus marimastat in patients with recurrent malignant glioma...
  36. ncbi Recent advances in therapy for glioblastoma
    Jennifer Clarke
    Division of Neuro Oncology, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Ave, Room A 808, Box 0372, San Francisco, CA 94143 0372, USA
    Arch Neurol 67:279-83. 2010
    ....
  37. ncbi Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging
    Soonmee Cha
    Department of Radiology, University of California-San Francisco, UCSF Medical Center, 505 Parnassus Avenue, San Francisco, CA 94143-0628, USA
    AJNR Am J Neuroradiol 26:266-73. 2005
    ..Our findings suggest that tumor rCBV(max) derived from DSC MR imaging can be used to distinguish between the two low-grade gliomas...
  38. ncbi Gliomatosis cerebri: a review of 22 cases
    G Edward Vates
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA
    Neurosurgery 53:261-71; discussion 271. 2003
    ....
  39. ncbi Genetic aberrations in gliomatosis cerebri
    Marcus L Ware
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA
    Neurosurgery 60:150-8; discussion 158. 2007
    ....
  40. ncbi Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas
    Xiaojuan Li
    Magnetic Resonance Science Center, Department of Radiology, University of California, San Francisco, 1 Irving St, San Francisco, CA 94143, USA
    NMR Biomed 17:10-20. 2004
    ....
  41. ncbi Considerations in applying 3D PRESS H-1 brain MRSI with an eight-channel phased-array coil at 3 T
    Yan Li
    UCSF/UCB Joint Graduate Group in Bioengineering, San Francisco, CA 94720, USA
    Magn Reson Imaging 24:1295-302. 2006
    ..5 T with a quadrature head coil. This is expected to be critical for clinical applications of MRSI in patients with brain tumors because it can be used to either decrease acquisition time or improve spatial resolution...
  42. ncbi The superiority of conservative resection and adjuvant radiation for craniopharyngiomas
    Adam Schoenfeld
    Department of Radiation Oncology, University of California, San Francisco UCSF, San Francisco, CA 94143 1708, USA
    J Neurooncol 108:133-9. 2012
    ..014). In conclusion, for patients with craniopharyngioma, STR + RT may provide superior clinical outcome, achieving better disease control than STR and limiting side effects associated with aggressive surgical resection...
  43. ncbi Pseudoprogression and pseudoresponse: challenges in brain tumor imaging
    Jennifer L Clarke
    Department of Neurological Surgery, Division of Neuro Oncology, University of California San Francisco, 400 Parnassus Avenue, A 808, Box 0372, San Francisco, CA 94143, USA
    Curr Neurol Neurosci Rep 9:241-6. 2009
    ..This article reviews the challenges of brain tumor imaging and its use in assessment of treatment response...
  44. ncbi Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility
    Margaret Wrensch
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA
    Nat Genet 41:905-8. 2009
    ..85 x 10(-10). On 20q13.3, rs6010620 intronic to RTEL1 had discovery P = 1.5 x 10(-7), replication P = 0.00035 and combined P = 3.40 x 10(-9). For both SNPs, the direction of association was the same in discovery and replication phases...
  45. ncbi Grade II astrocytomas are subgrouped by chromosome aberrations
    Yuichi Hirose
    Department of Neurological Surgery, University of California, San Francisco, CA 94115, USA
    Cancer Genet Cytogenet 142:1-7. 2003
    ..The comparatively large number of cases in this study allows us to suggest that these tumors are genetically subgrouped...
  46. ncbi Factors influencing overall survival rates for patients with pineocytoma
    Aaron J Clark
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94117, USA
    J Neurooncol 100:255-60. 2010
    ..Gross total resection is the most appropriate treatment for pineocytoma. The potential benefit of conventional radiotherapy for the treatment of these lesions is unproven, and little evidence supports its use at present...
  47. ncbi Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors
    D Vigneron
    Department of Radiology, University of California, San Francisco, CA 94143, USA
    Magn Reson Imaging 19:89-101. 2001
    ..The results of this study indicate that 3D MRSI of brain tumors can detect abnormal metabolite levels in regions of viable cancer and grades and can differentiate cancer from necrosis and/or normal brain tissue...
  48. ncbi Mice lacking 25OHD 1alpha-hydroxylase demonstrate decreased epidermal differentiation and barrier function
    D D Bikle
    Department of Medicine, Veterans Affairs Medical Center, University of California, 4150 Clement Street 111N, San Francisco, CA 94121, USA
    J Steroid Biochem Mol Biol 89:347-53. 2004
    ..Thus 1,25(OH)(2)D is essential for normal epidermal differentiation, most likely by inducing the proteins and mediating the calcium signaling in the epidermis required for the generation and maintenance of the barrier...
  49. ncbi Volume MRI and MRSI techniques for the quantitation of treatment response in brain tumors: presentation of a detailed case study
    S J Nelson
    Department of Radiology, University of California, San Francisco 94143, USA
    J Magn Reson Imaging 7:1146-52. 1997
    ....
  50. ncbi Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid
    J G Kahn
    Institute for Health Policy Studies, Department of Epidemiology and Biostatistics, University of California, San Francisco 94143, USA
    Am J Public Health 91:1464-73. 2001
    ..OBJECTIVES. This study modeled the health and federal fiscal effects of expanding Medicaid for HIV-infected people to improve access to highly active antiretroviral therapy...
  51. ncbi 25 Hydroxyvitamin D 1 alpha-hydroxylase is required for optimal epidermal differentiation and permeability barrier homeostasis
    D D Bikle
    Department of Medicine, Veterans Affairs Medical Center and University of California, San Francisco 94121, USA
    J Invest Dermatol 122:984-92. 2004
    ....
  52. ncbi Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme
    P K Sneed
    Department of Radiation Oncology, University of California, San Francisco 94143 0226, USA
    Int J Radiat Oncol Biol Phys 40:287-95. 1998
    ..To determine if adjuvant interstitial hyperthermia (HT) significantly improves survival of patients with glioblastoma undergoing brachytherapy boost after conventional radiotherapy...
  53. ncbi Low-grade gliomas in adults
    Nader Sanai
    Barrow Brain Tumor Research Center, Department of Neurological Surgery, Barrow Neurological Institute, Phoenix, Arizona, USA
    J Neurosurg 115:948-65. 2011
    ..In this article, the authors evaluate the recent literature to synthesize a comprehensive review of LGGs in the modern neurosurgical era...
  54. ncbi Filming the family: a documentary film to educate clinicians about family caregivers of patients with brain tumors
    Michael W Rabow
    Department of Medicine, University of California, San Francisco, CA, USA
    J Cancer Educ 25:242-6. 2010
    ..009). A documentary film about family caregiving is an effective educational tool to increase awareness among neurosurgery/neuro-oncology clinicians about the importance and needs of family caregivers of patients with brain tumors...
  55. ncbi Effects of a telephone counseling intervention on sisters of young women with breast cancer
    Joan R Bloom
    University of California, 409 Warren Hall, Berkeley, CA 94720 7360, USA
    Prev Med 43:379-84. 2006
    ..An intervention to provide objective risk information, reduce worries, and promote screening and healthy behaviors was developed...
  56. ncbi Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery
    E E Graves
    Departments of Radiology, University of California, San Francisco 94143, USA
    AJNR Am J Neuroradiol 22:613-24. 2001
    ..Evaluation of metabolic changes with proton MR spectroscopy and structural changes with MR imaging improved tissue discrimination and provided correlation with histologic findings...
  57. ncbi Radiosurgery for brain metastases from primary lung carcinoma
    R Hoffman
    Department of Radiation Oncology, University of California, San Francisco 94143-0226, USA
    Cancer J 7:121-31. 2001
    ..Prospective, randomized trials are needed to further investigate the role of radiosurgery with and without whole-brain radiotherapy for brain metastases...
  58. ncbi Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder
    S Saxena
    Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA 92161, USA
    Mol Psychiatry 14:197-205. 2009
    ....
  59. ncbi Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study
    Monica E Loghin
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:7133-8. 2007
    ..The study was also intended to assess whether temozolomide affects the conversion of irinotecan to SN-38...
  60. ncbi Current chemotherapy for glioblastoma
    Ian F Parney
    Neuro-Oncology Service, Department of Neurological Surgery, University of California San Francisco, San Francisco, California 94143-0350, USA
    Cancer J 9:149-56. 2003
    ..Strategies currently in clinical trials may improve this impact more in the future...
  61. ncbi Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results
    Michael A Vogelbaum
    Brain Tumor and Neuro Oncology Center, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Neurosurgery 61:1031-7; discussion 1037-8. 2007
    ....
  62. ncbi Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial
    Michael D Prados
    University of California, San Francisco, USA
    J Neurooncol 65:269-78. 2003
    ..This treatment modality is feasible and appears to have some evidence of efficacy. Toxicity may be related in part to the method of gene delivery...
  63. ncbi Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings
    Ilwoo Park
    Surbeck Laboratory of Advanced Imaging, Department of Radiology, University of California San Francisco, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 69:381-9. 2007
    ....
  64. ncbi Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma
    John G Kuhn
    Pharmacotherapy Education and Research Center, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    Clin Cancer Res 13:7401-6. 2007
    ..An additional objective was to determine whether concentrations of temsirolimus or sirolimus were achieved in brain tumor tissue...
  65. ncbi Development of a robust method for generating 7.0 T multichannel phase images of the brain with application to normal volunteers and patients with neurological diseases
    Kathryn E Hammond
    University of California San Francisco Berkeley Joint Graduate Group in Bioengineering, San Francisco, CA 94158 2532, USA
    Neuroimage 39:1682-92. 2008
    ..5 T. The clinical images showed novel contrast in MS plaques and depicted microhemorrhages and abnormal vasculature in brain tumors with unsurpassed resolution and contrast...
  66. ncbi Three-dimensional J-resolved H-1 magnetic resonance spectroscopic imaging of volunteers and patients with brain tumors at 3T
    Yan Li
    University of California, San Francisco University of California, Berkeley Joint Graduate Group in Bioengineering, San Francisco, California 94143 2532, USA
    Magn Reson Med 58:886-92. 2007
    ..17 Hz. This technique also enables the evaluation of the changes in metabolite T(2). Compared with the values in normal white matter, the T(2) values of Cho and Cr were statistically significantly increased in regions of glioma...
  67. ncbi Seizure characteristics and control following resection in 332 patients with low-grade gliomas
    Edward F Chang
    Department of Neurological Surgery and Brain Tumor Research Center, University of California, San Francisco, California 94143, USA
    J Neurosurg 108:227-35. 2008
    ..The aim of this study was to identify factors that influenced perioperative seizure characteristics and postoperative seizure control...
  68. ncbi Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas
    Justin S Smith
    Department of Neurological Surgery, Brain Tumor Research Center, University of California San Francisco, 505 Parnassus Ave, Room M 779, San Francisco, CA 94143 0112, USA
    J Clin Oncol 26:1338-45. 2008
    ..The prognostic role of extent of resection (EOR) of low-grade gliomas (LGGs) is a major controversy. We designed a retrospective study to assess the influence of EOR on long-term outcomes of LGGs...
  69. ncbi Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas
    Kathleen R Lamborn
    Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, UC Clinics 808, San Francisco, CA 94143 0372, USA
    Neuro Oncol 10:162-70. 2008
    ..Earlier assessments of progression status also predicted survival and may be incorporated in the design of future clinical trials...
  70. ncbi Relationship between choline and apparent diffusion coefficient in patients with gliomas
    Inas S Khayal
    University of California, San Francisco, California, USA
    J Magn Reson Imaging 27:718-25. 2008
    ....
  71. ncbi Comparison of T(1) and T(2) metabolite relaxation times in glioma and normal brain at 3T
    Yan Li
    University of California, San Francisco University of California, Berkeley UCSF UCB Joint Graduate Group in Bioengineering, San Francisco, California 94143 2532, USA
    J Magn Reson Imaging 28:342-50. 2008
    ..To measure T(1) and T(2) relaxation times of metabolites in glioma patients at 3T and to investigate how these values influence the observed metabolite levels...
  72. ncbi Malignant pineal parenchymal tumors in adult patients: patterns of care and prognostic factors
    Johannes Lutterbach
    Abteilung Strahlenheilkunde, Radiologische Universitatsklinik, Freiburg im Breisgau, Germany
    Neurosurgery 51:44-55; discussion 55-6. 2002
    ..The aim of our study was to analyze patterns of care and to identify prognostic factors in patients at least 18 years of age who received radiotherapy for malignant pineal parenchymal tumors...
  73. ncbi A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study
    H Ian Robins
    Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
    Neuro Oncol 4:109-14. 2002
    ..The significant myeloprotection afforded by thymidine may have particular relevance to polychemotherapeutic regimens...
  74. ncbi Repeated operations for infiltrative low-grade gliomas without intervening therapy
    Meic H Schmidt
    Department of Neurological Surgery, University of California at San Francisco, California, USA
    J Neurosurg 98:1165-9. 2003
    ..The authors examined factors that may be associated with tumor progression...
  75. ncbi Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy
    G Evren Keles
    Department of Neurological Surgery, University of California, San Francisco, California 94143 0112, USA
    J Neurosurg 100:41-6. 2004
    ..To accomplish this, the authors evaluated a homogeneous group of patients with recurrent GBMs who received the same chemotherapeutic agent...
  76. ncbi Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme
    Nicholas Butowski
    Neuro Oncology Service, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0350, USA
    J Neurooncol 85:87-94. 2007
    ..Patients treated during surgically based phase II studies should be matched with a historical control group restricted to patients with similar pretreatment variables, including GTR...
  77. ncbi O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas
    S Clifford Schold
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Neuro Oncol 6:28-32. 2004
    ..We conclude that a BG dose of 120 mg/m(2) given 6 h before an alkylating drug would be effective in suppressing AGT and possibly potentiating the cytotoxic effects of the drug...
  78. ncbi Partial-volume model for determining white matter and gray matter cerebral blood volume for analysis of gliomas
    Michael C Lee
    Department of Radiology, University of California San Francisco, UCSF Radiology Box 2532, 1700 4th Street, San Francisco, CA 94143, USA
    J Magn Reson Imaging 23:257-66. 2006
    ....
  79. ncbi Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis
    Kathleen R Lamborn
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0112, USA
    Neuro Oncol 6:227-35. 2004
    ....
  80. ncbi Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma
    Antoinette A Chan
    Department of Radiology, University of California, San Francisco, California 94107-1739, USA
    J Neurosurg 101:467-75. 2004
    ..This difference was statistically significant (p < 0.01). CONCLUSIONS: Analysis of the results of this study indicates that patients undergoing GKS may benefit from the inclusion of 1H-MRS imaging in the treatment planning process...
  81. ncbi Brain metastases
    Mark E Shaffrey
    Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia, USA
    Curr Probl Surg 41:665-741. 2004
  82. ncbi Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme
    Susan M Chang
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 60:353-7. 2004
    ..It is unclear the added advantage thalid has in combination with TMZ for this patient population...
  83. ncbi Marital status, treatment, and survival in patients with glioblastoma multiforme: a population based study
    Susan M Chang
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA
    Cancer 104:1975-84. 2005
    ....
  84. ncbi Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study
    Vinay K Puduvalli
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston TX 77030, USA
    J Clin Oncol 22:4282-9. 2004
    ..Fenretinide induces apoptosis in malignant gliomas in vitro. This two-stage phase II trial was conducted to determine the efficacy of fenretinide in adults with recurrent malignant gliomas...
  85. ncbi Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma
    Ian F Parney
    Department of Neurological Surgery, Brain Tumor Research Center, University of California at San Francisco, California 94143-0350, USA
    J Neurosurg 102:267-75. 2005
    ....
  86. ncbi Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity
    Janine M Lupo
    Department of Radiology, University of California, San Francisco, USA
    AJNR Am J Neuroradiol 26:1446-54. 2005
    ..Peak height and percent recovery parameters help to improve the specificity for characterization of the degree of angiogenesis and microvascular leakage in these tumors and may be useful in evaluating response to treatment...
  87. ncbi Dynamic susceptibility contrast perfusion imaging of radiation effects in normal-appearing brain tissue: changes in the first-pass and recirculation phases
    Michael C Lee
    Department of Radiology, University of California San Francisco, San Francisco, California 94143 2532, USA
    J Magn Reson Imaging 21:683-93. 2005
    ..To identify radiation-induced changes in the cerebral vasculature of healthy tissue in the first four months following radiotherapy through the analysis of dynamic-susceptibility contrast perfusion imaging...
  88. ncbi Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults
    Andrew T Parsa
    Department of Neurological Surgery, School of Medicine, University of California at San Francisco, California 94143, USA
    J Neurosurg 102:622-8. 2005
    ..The objective in the present study was to assess the prognostic significance of disseminated intracranial GBM in adults at presentation and at the time of tumor progression...
  89. ncbi Small molecule and monoclonal antibody therapies in neurooncology
    Nicholas Butowski
    Department of Neurological Surgery, University of California, San Francisco, CA 94143-0350, USA
    Cancer Control 12:116-24. 2005
    ..Further study of these agents in well-designed cooperative clinical trials is needed...
  90. ncbi A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma
    Nicholas Butowski
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 61:1454-9. 2005
    ..Based on this study, cRA does not seem to add a significant synergistic effect to TMZ and XRT...
  91. ncbi Diagnosis and treatment of recurrent high-grade astrocytoma
    Nicholas A Butowski
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143-0350, USA
    J Clin Oncol 24:1273-80. 2006
    ....
  92. ncbi Unaliasing lipid contamination for MR spectroscopic imaging of gliomas at 3T using sensitivity encoding (SENSE)
    Esin Ozturk-Isik
    UCSF UCB Joint Graduate Group in Bioengineering, University of California San Francisco, San Francisco, California 94143 2532, USA
    Magn Reson Med 55:1164-9. 2006
    ....
  93. ncbi Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme
    David A Larson
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:119-26. 2004
    ..We conclude that permanent 125I brachytherapy for recurrent or progressive GM is well tolerated. Survival time was comparable to that of a similar group of patients treated with temporary brachytherapy...
  94. ncbi Treatment for posterior fossa dissemination of primary supratentorial glioma
    Justin S Smith
    Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, California 94143 0350, USA
    J Neurosurg 106:567-74. 2007
    ..This study was designed to assess the presentation, management, and outcome of cases involving patients who had a supratentorial glioma that subsequently progressed in the posterior fossa (PF)...
  95. ncbi Glial tumors: the current state of scientific knowledge
    Nicholas A Butowski
    Department of Neurological Surgery, University of California, San Francisco, USA
    Clin Neurosurg 53:106-13. 2006
  96. ncbi Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group
    Sandeep Kunwar
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143 0350, USA
    J Clin Oncol 25:837-44. 2007
    ..We assessed the use of intracerebral CED to deliver CB in patients with recurrent malignant glioma (MG)...
  97. ncbi Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study
    Michael D Prados
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:33-7. 2004
    ..We conclude that BCNU plus temozolomide when used in these doses and schedule has only modest activity, with significant toxicity, and appears to be no more effective than single-agent temozolomide...
  98. ncbi Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
    Michael D Prados
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:44-54. 2004
    ..A phase 2 study of patients with recurrent malignant glioma is ongoing to assess the efficacy of CPT-11 when the dose is stratified according to the use of EIAEDs...
  99. ncbi A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme
    Morris D Groves
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, 1400 Holcombe, 431, Houston, TX, 77030, USA
    J Neurooncol 81:271-7. 2007
    ..Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)...
  100. ncbi Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury
    Justin S Smith
    Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco School of Medicine, San Francisco, California 94143 0112, USA
    J Neurosurg 103:428-38. 2005
    ..The purpose of this study was to investigate prospectively the incidence, time course, and ultimate outcome of these abnormalities...
  101. ncbi Feasibility of dynamic susceptibility contrast perfusion MR imaging at 3T using a standard quadrature head coil and eight-channel phased-array coil with and without SENSE reconstruction
    Janine M Lupo
    Department of Radiology, University of California San Francisco, San Francisco, California 94158, USA
    J Magn Reson Imaging 24:520-9. 2006
    ..5t...

Research Grants2

  1. NABTC Member Intitution Grant (UCSF Project Leader)
    Susan Chang; Fiscal Year: 2007
    ..The overall goal of this program is to more effectively treat patients with primary brain tumors, especially malignant glioma, with the purpose of increasing the duration and quality of survival. ..